The Generalized Pustular Psoriasis (GPP) drugs in development market research report provides comprehensive information on the therapeutics under development for Generalized Pustular Psoriasis (GPP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Generalized Pustular Psoriasis (GPP). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Generalized Pustular Psoriasis (GPP) and features dormant and discontinued products.
GlobalData tracks six drugs in development for Generalized Pustular Psoriasis (GPP) by five companies/universities/institutes. The top development phase for Generalized Pustular Psoriasis (GPP) is preclinical with two drugs in that stage. The Generalized Pustular Psoriasis (GPP) pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Generalized Pustular Psoriasis (GPP) pipeline products market are: Huabo Biopharm (Shanghai), JiangSu Qyuns Therapeutics and Inmagene Biopharmaceuticals.
The key targets in the Generalized Pustular Psoriasis (GPP) pipeline products market include Interleukin 1 Receptor Like 2 (IL 36 Receptor or Interleukin 1 Receptor Related Protein 2 or IL1RL2), and Interleukin 17 (IL17).
The key mechanisms of action in the Generalized Pustular Psoriasis (GPP) pipeline product include Interleukin 1 Receptor Like 2 (IL 36 Receptor or Interleukin 1 Receptor Related Protein 2 or IL1RL2) Antagonist with five drugs in Pre-Registration. The Generalized Pustular Psoriasis (GPP) pipeline products include two routes of administration with the top ROA being Intravenous and one key molecule types in the Generalized Pustular Psoriasis (GPP) pipeline products market including Monoclonal Antibody.
Generalized Pustular Psoriasis (GPP) overview
Pustular psoriasis is a rare and extreme form of psoriasis characterized by the appearance of sterile pustules which can take many patterns. All the main pathological features of the disease are accentuated. Generalized pustular psoriasis is clinically heterogeneous in its age at onset, precipitants, severity, and natural history. Generalized pustular psoriasis is often associated with metabolic syndrome and polyarthritis
For a complete picture of Generalized Pustular Psoriasis (GPP)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
